hematologic malignancies, primarily loss of function variants in epigenetic modifiers TET2, ASXL1, DNTM3A, as well as JAK2 VF . Although clonal hematopoiesis (CH) was associated with an increased risk of hematologic malignancies, unexpectedly there was also a 2 to 3 fold increase in the risk of atherosclerotic cardiovascular disease (CVD), identifying CH as a major risk factor for CVD in the elderly. Moreover, the prevalence of CH increases from age 40 years onward, and CH mutations increase the risk of early-onset myocardial infarction (<50 years old) by 4 fold. Although less common than the epigenetic modifier variants, the increase in risk appears to be strongest for the JAK2 VF variant (12-fold increase in CVD). Although the association of CH with atherosclerosis in human populations could be confounded by aging, a causal relationship between TET2 deficiency and atherosclerosis was shown in mouse models with pan-hematopoietic or myeloid TET2 deficiency, and increased macrophage inflammation was implicated as an underlying mechanism. 9, 10 Whether the same or different atherogenic mechanisms are involved in the effects of other CH mutations is not known. In this study, we have assessed atherosclerosis in mice with hematopoietic Jak2 VF expression and explored the underlying mechanisms.
Methods
The authors declare that all supporting data, analytical methods, and materials developed from this group within the article and its Online Data Supplement files are available.
A detailed description of methods and materials is provided in the Online Data Supplement.
Results

Increased Atherosclerosis in Jak2 VF Mice
To assess the impact of hematopoietic Jak2 VF expression on atherosclerosis, sublethally irradiated wild-type (WT) or Ldlr −/− mice were transplanted with WT or Jak2 VF expressing bone marrow (BM) cells. 11 To assess a possible interaction of the mutation with hypercholesterolemia, WT recipients were fed a chow diet, and Ldlr −/− recipients were fed Western diet (WD). Although WT recipients fed the chow diet remained normocholesterolemic, WD feeding caused progressive hypercholesterolemia in Ldlr −/− recipients (Online Figure IA) . However, the increase in plasma cholesterol caused by the WD was less pronounced in the Ldlr −/− mice receiving Jak2 VF BM (≈30% lower after 7 weeks; P<0.01), reflecting reduced VLDL (very low-density lipoprotein)+LDL cholesterol levels as shown elsewhere, 12 which may reflect increased uptake of LDL by expanded myeloid cells 13 or inflammatory cytokine effects on hepatic production.
14 Plasma HDL (high-density lipoprotein) cholesterol in WD-fed mice (Online Figure   Nonstandard Abbreviations What New Information Does This Article Contribute?
• Hematopoietic Jak2 VF expression in Ldlr −/− mice promotes neutrophilenriched early lesion formation.
• Advanced lesions show increased necrotic cores, defective efferocytosis, and prominent erythrophagocytosis • Jak2 VF macrophages displayed increased expression of proinflammatory cytokines and inflammasome activation, possibly driving neutrophil entry into lesions.
• Jak2 VF erythrocytes undergo increased uptake by macrophages (erythrophagocytosis), leading to impaired uptake of apoptotic cells (efferocytosis), which together with increased cleavage of MerTK (c-Mer tyrosine kinase), promotes necrotic core formation and plaque instability.
Jak2
VF , a gain of function mutation that is commonly found in elderly patients with myeloproliferative neoplasms or clonal hematopoiesis, is associated with increased risk of atherothrombotic diseases. In Ldlr −/− mice expressing Jak2 VF in hematopoietic tissues, we showed accelerated early atherosclerosis and increased complexity of advanced lesions, despite lower levels of LDL (low-density lipoprotein) cholesterol. Early lesions showed increased binding of neutrophils to endothelium and increased numbers of neutrophils in plaques. More advanced lesions showed increased necrotic cores, defective efferocytosis, and erythrophagocytosis. Erythrophagocytosis refected a Jak2 VF intrinsic red cell defect. Defective efferocytosis was linked to macrophage inflammation and MerTK cleavage and to competition between red cells and apoptotic cells for macrophage uptake. These studies provide direct evidence that Jak2 VF increases atherogenesis, involving different hematopoietic lineages and their interactions.
V617F Promotes Atherosclerosis e37 IB) or plasma total cholesterol in chow diet-fed mice (Online Figure IC) showed no change. Plasma triglyceride levels were also decreased in WD-fed Jak2 VF recipients (Online Figure ID) . Relative to the WT recipients, Jak2 VF recipients displayed expansion of hematopoietic stem and progenitor cells, erythrocyte, and megakaryocyte progenitors in BM (Online Figure IE) and marked erythrocytosis, thrombocytosis, and neutrophilia (Online Figure IF-IJ) , as reported, 11 on both chow and WD diets. There was marked erythrocyte microcytosis and anisocytosis (Online Figure IIA and IIB) .
VF also markedly increased platelet/monocyte and platelet/neutrophil aggregates (Online Figure IIC and IID) , likely reflecting increased platelet and leukocyte counts and increased platelet activation as evidenced by increased surface P-selectin presentation in the basal or PAR4 (protease-activated receptor) agonist (AYPGKF)-stimulated state (Online Figure IIE and IIF) . The increases in hematopoietic stem and progenitor cell counts (Online Figure IE) , neutrophilia (Online Figure IJ) , platelet/monocyte and platelet/neutrophil aggregates (Online Figure IIC and IID) , and platelet surface P-selectin (Online Figure IIE) in Jak2 VF were significantly more pronounced on the WD (P<0.05) as assessed by 2-way ANOVA and Sidak post hoc test for multiple comparisons.
Despite the lower plasma cholesterol levels, atherosclerotic lesion size in the aortic root was increased by 1.6 fold in Jak2 Figure IIIB) . Lesional MPO (myeloperoxidase), another neutrophil marker which largely overlapped with the Ly6G marker in lesional cells ( Figure 1B) , was also markedly increased in early lesions of Jak2 VF recipients ( Figure 1D ) and correlated with lesion size (Figure 1E ), consistent with a proatherogenic role of neutrophils in early atherogenesis. 15 Intravital fluorescence microscopy showed a marked increase in neutrophil rolling and firm adhesion on early carotid artery lesions in Jak2 VF recipients ( 
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November 9, 2018 IIID). Neutrophils from WD-fed Jak2 VF recipients showed evidence of activation with increased expression of FPR1 (formyl peptide receptor 1) and adhesion molecule CD11b ( Figure 2D and 2E). Neutrophils displayed increased adhesion to recombinant cell adhesion molecules ( Figure 2F and 2G). Thus, in addition to neutrophilia, neutrophil activation likely contributed to increased adhesion and entry of neutrophils into early atherosclerotic plaques.
In mice fed the WD for 12 weeks, plasma total cholesterol and triglyceride levels were ≈50% lower in Jak2 VF recipients (Online Figure IVA and IVB). Despite the markedly reduced cholesterol and triglyceride levels, lesion size showed a trend to be increased (1.3 fold; P=0.07) in the Jak2 VF recipients ( Figure 3A ). Necrotic core area, a well-established index of plaque instability, 16 was significantly increased both in absolute terms (area of necrotic core per section, 1.7 fold increase) or relative to lesion size (% of total lesion area, 1.4 fold increase; Figure 3B -3D) in Jak2 VF recipients compared with controls. Lesional macrophages ( Figure 3E ), but not neutrophils, (Online Figure IVC) were increased in advanced lesions of Jak2 VF recipients. Unlike in early lesions, lesional neutrophil count showed no significant correlation with lesion area in advanced lesions (Online Figure IVD) . Collagen content and fibrous cap thickness did not show differences between the genotypes in advanced lesions (Online Figure IVE) . 
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VF Increases Lesional Erythrophagocytosis in Advanced Atherosclerosis
Increased hematocrit, as well as abnormalities in red blood cell (RBC) morphology in Jak2 VF mice (Online Figure IF ; Online Figure IIA and IIB), suggested a possible role of erythrocytes in atherosclerosis. 17 To assess this, we stained lesions for iron and erythrocytes. Although WT recipients showed little lesional iron deposition, iron staining was clearly identified in the majority of Jak2 VF recipients in advanced lesions ( Figure 4A ; Online Figure IVF , P<0.05, χ 2 test). Staining of Ter119, a specific erythrocyte marker, was also increased in advanced lesions of Jak2 VF recipients ( Figure 4A , Online Figure  IVG , P<0.05, χ 2 test). Interestingly, when the Ter119 positive sections were stained with antibodies against the macrophage marker Mac-3 (CD107b), the 2 markers were largely colocalized ( Figure 4A ), suggesting erythrophagocytosis. Notably, macrophages containing erythrocyte markers were primarily found on the periphery of necrotic cores ( Figure 4A ), particularly in 7 week early lesions (Online Figure VA) .
To assess potential pathways for entry of RBCs into lesions, we assessed VWF (von Willebrand factor) staining.
However, there was little staining in advanced lesions and no difference between Jak2 VF and WT recipients (not shown). We did detect a marked increase in erythrocyte/neutrophil and erythrocyte/monocyte complexes in the circulation in Jak2 VF recipients (Online Figure VB) , suggesting the possibility that erythrocyte/leukocyte complex formation facilitates RBC entry via the luminal surface of plaques.
Jak2
VF Erythrocytes Are More Susceptible to Erythrophagocytosis
To gain insights into the mechanism of erythrophagocytosis in lesions, we incubated WT or Jak2 VF erythrocytes with WT or Jak2 VF macrophages and assessed erythrophagocytosis by fluorescence microscopy. Jak2 VF erythrocytes showed increased uptake by either WT or Jak2 VF macrophages ( Figure 4B ). Erythrophagocytosis rather than surface binding of erythrocytes by phagocytes was confirmed by reconstructed 3D images obtained by fluorescence confocal microscopy, as well as overlay on bright field images (Online Figure VIA and VIB) . To assess whether the findings of aberrant erythrophagocytosis with mouse Jak2 VF erythrocytes could be recapitulated with human erythrocytes, we obtained human blood samples from JAK2VF positive MPN patients and matched control human subjects. These patients were newly identified, nontreated, or being treated with aspirin or phlebotomy but not with hydroxyurea or ruxolitinib. Incubation of human erythrocytes with human macrophages derived from peripheral blood mononuclear cells of healthy human subjects also resulted in robust erythrophagocytosis (Online Figure VIC) . Quantification of erythrophagocytosis by flow cytometry indicated increased erythrophagocytosis of JAK2VF erythrocytes compared with control erythrocytes (Figure 4C and 4D) . 
Erythrocytes
Accelerated erythrocyte aging has been proposed to explain increased erythrophagocytosis in some erythrocytosis models.
18
Increased erythrocyte band 4.1a/4.1b ratio has been used as a marker for erythrocyte senescence. 18 Band 4.1a/4.1b ratio in 
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V617F Promotes Atherosclerosis e41 mouse Jak2 VF erythrocytes was not altered relative to the WT erythrocytes (Online Figure VID) , suggesting no change of erythrocyte senescence. However, we noticed that band 4.2 was markedly decreased in Jak2 VF erythrocytes (Online Figure VID  and VIE) . Band 4.2 deficiency has been linked to accelerated erythrocyte clearance and marked reduction of CD47, 19 ,20 a molecule protecting erythrocytes from fortuitous phagocytosis by macrophages. 21 We assessed erythrocyte surface CD47 levels by flow cytometry and found a significant reduction in Jak2 VF erythrocytes ( Figure 5A and 5B). In contrast, human Jak2 VF erythrocytes did not show a decrease in surface CD47 (not shown) but rather displayed increased surface calreticulin ( Figure 5C ), consistent with a recent report. 22 Surface calreticulin counteracts CD47 signaling and promotes phagocytosis of erythrocytes. 23 These results suggest distinct mechanisms promoting erythrophagocytosis of human versus mouse Jak2 VF erythrocytes.
Defective Efferocytosis in Advanced Lesions in Jak2 VF Mice
A body of work indicates that efficient efferocytosis of apoptotic cells by lesional macrophages is a key event limiting necrotic core formation in advanced atherosclerosis. [24] [25] [26] The increased necrotic core in advanced lesions of Jak2 VF mice led us to assess lesional efferocytosis. The ratio of free versus macrophage-associated apoptotic cells was markedly increased in advanced lesions of Jak2 VF mice ( Figure 6A ), indicating defective efferocytosis. Macrophage MerTK (c-Mer tyrosine kinase) serves as a cell surface receptor and signaling molecule mediating efferocytosis, and MerTK has a central role in promoting efferocytosis and decreasing necrotic core formation in atherosclerotic lesions. 24, 27 We thus assessed surface MerTK levels in vivo in splenic macrophages and levels of soluble MerTK, the product of surface MerTK cleavage, generated from the cultured macrophages of WT and Jak2 VF mice. This showed increased cleavage (inset, Figure 6B ) and markedly decreased cell surface MerTK levels ( Figure 6B ) in Jak2 VF compared with WT macrophages, whereas plasma soluble MerTK levels showed no change (Online Figure VIF) . Importantly, MerTK levels in lesional macrophages were markedly decreased in advanced lesions of Jak2 VF mice ( Figure 6C ; Online Figure VIG and VIH). Next, we assessed the potential impact of erythrophagocytosis on efferocytosis ex vivo. Coincubation of WT or Jak2 VF macrophages with erythrocytes and apoptotic Jurkat cells led to suppression of efferocytosis of Jurkat cells relative to incubation with Jurkat cells alone ( Figure 6D ). WT and Jak2 VF macrophages did not show difference in efferocytosis. In contrast, Jak2 VF erythrocytes caused a more pronounced suppression of efferocytosis in both WT and Jak2 VF macrophages ( Figure 6D) , likely reflecting the increased susceptibility of Jak2 VF erythrocytes to erythrophagocytosis. Together, these findings suggest that increased uptake of erythrocytes in combination with decreased uptake of apoptotic cells by lesional macrophages contributes to advanced lesion complexity, including increased necrotic core formation in Jak2 VF mice.
Increased Inflammatory Activation of Jak2
VF
Macrophage
To assess inflammatory responses, we challenged WT or Jak2 VF macrophages with lipopolysaccharide (LPS), a stimulus relevant to TLR4/MyD88 (toll-like receptor/myeloid differentiation primary response 88) and TLR4/TRIF (TLR4/ TIR [Toll/interleukin 1 receptor]-domain-containing adapter-inducing INF [interferon]-β) signaling pathways that are known to promote atherogenesis. 28, 29 Jak2 VF macrophages showed increased expression of proinflammatory cytokines and chemokines, that is, IL (interleukin)-1β, IL-6, iNOS (inducible nitric oxide synthase), Tnf-α (tumor necrosis factor), and MCP-1 (monocyte chemoattractant protein 1; Figure 7A ; Online Figures IX, XB, and XI). Although IL-6 secretion from Jak2 VF macrophages was markedly increased, the increase in IL-1β secretion after 8-hour LPS stimulation was only moderate (Online Figure VIIA and VIIB) , and less pronounced than the increase in IL-1β mRNA levels ( Figure 7A ). Prominent IL-1β secretion requires inflammasome activation. 30 Indeed, Figure 5 . Jak2 VF mice showed reduced surface CD47 expression in erythrocytes. Erythrocytes were from chow-fed female mice. 
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ATP-stimulated IL-1β production from Jak2 VF macrophages was increased more pronouncedly relative to wild-type cells ( Figure 7B ), consistent with inflammasome activation. To evaluate the relevance in vivo, we examined inflammasome activation by assessing caspase-1 and caspase-11 cleavage in splenic CD11b + or CD11b − cells. This was markedly increased in Jak2 VF CD11b + ( Figure 7C ) but not WT CD11b + ( Figure 7C ) or Jak2 VF or WT CD11b − cells (not shown), suggesting activation of both NLRP3 (NLR family pyrin domain-containing 3) and noncanonical, Caspase-11 dependent macrophage inflammasomes. 31 Markedly increased IL-1β production from the freshly isolated splenic Jak2 VF CD11b + cells, particularly in response to LPS, was also consistent with inflammasome activation in vivo ( Figure 7D ). Additional evidence showing inflammasome activation came from the finding that plasma levels of IL-18, which production depends on and is considered as a marker of inflammasome activation in vivo, 32 were markedly increased in Jak2 VF mice ( Figure 7E ). Although increased proinflammatory responses to LPS were consistently detected in briefly cultured concanavalin A (ConA)-elicited mouse peritoneal macrophages ( Figure 7A ; Online Figure VIIC) , the responses were less prominent in BM-derived macrophages cultured for 7 days (Online Figure  VIID) . ConA is known to induce T-cell proliferation and IFNγ responses in vivo 33 and JAK2 has an essential role in mediating IFNγ signaling. 34 To explore the possibility that macrophages were primed for increased signaling in ConA-treated Jak2 VF mice, we assessed multiple molecules mediating IFNγ and JAK2 signaling. Levels of phosphorylated p38, JNK (cJun N-terminal kinase), and AKT in the non-LPS treated basal state were significantly increased in ConA-elicited Jak2 VF macrophages, after a brief 6-hour culture in vitro (Online Figure  VIIIA) , and this was largely reversed after 48 hours in culture (Online Figure VIIIB) . Total and phosphorylated STAT1 (signal transducer and activator of transcription 1) were markedly decreased, a finding consistent with the negative feedback regulation of STAT1 by IFNγ signaling. 35 P38 and JNK are critical in mediating TLR4 initiated proinflammatory responses in macrophage. 36, 37 Inhibition of p38, JNK, or combined inhibition of p38 and JNK partially or completely reversed the LPS-induced proinflammatory responses of ConA-elicited Jak2 VF macrophages (Online Figure IX) , suggesting that increased priming had a major role in the enhanced inflammatory response to LPS. We also assessed the potential impact of altered endoplasmic reticulum stress or autophagy, which are known to regulate proinflammatory activation of macrophages. 38, 39 CHOP (CCAATenhancer-binding protein homologous protein) expression, a marker of endoplasmic reticulum stress, showed no difference between WT and Jak2 VF macrophages either in the basal or tunicamycin-induced endoplasmic reticulum stress state (Online Figure XA) . Rapamycin, an inducer of autophagy, decreased the expression of some cytokines in response to LPS, but the effect was proportionate for WT and Jak2 VF macrophages (Online Figure XB) . JAK1/2 inhibitor, such as ruxolitinib, has been approved as a treatment for JAK2VF positive MPN patients. 40 Notably, ruxolitinib reversed the increase in proinflammatory cytokine and chemokine expression in Jak2 VF macrophages, except for Tnf-α (Online Figure XI) . In contrast, ruxolitinib failed to reverse the increased susceptibility of Jak2 VF erythrocytes to erythrophagocytosis (Online Figure XC) .
Discussion
Our study demonstrates that hematopoietic Jak2 VF expression in hypercholesterolemic mice results in accelerated atherosclerosis with features of plaque instability, consistent with the increase in atherothrombotic CVD seen in patients with JAK2VF-associated MPN or CH. 9, 10, 12, 41 Increased neutrophil infiltration because of neutrophilia and neutrophil activation likely accounts for accelerated early lesion formation. In contrast, advanced atherosclerotic lesions displayed increased necrotic cores, increased macrophages, iron deposition, and evidence of erythrophagocytosis: similar features have been associated with atherosclerotic plaque instability in humans. 17 On a mechanistic level, Jak2 VF macrophages displayed increased cleavage and reduced surface levels of MerTK in association with defective efferocytosis in advanced lesions, likely contributing to increased necrotic core formation (Figure 8) . 42, 43 Jak2 VF macrophages showed increased inflammatory responses, including p38 MAPK (mitogen-activated protein kinase) activation likely promoting MerTK cleavage. 44 There was marked inflammasome activation in Jak2 VF macrophages leading to increased IL-1β secretion and increased IL-18 plasma levels. Increased production of macrophage inflammatory cytokines could contribute to increased neutrophil production and activation and entry of leukocytes into lesions. 45, 46 Augmented phagocytosis of RBC by macrophages likely reflected both increased RBC production, as well as intrinsic RBC defects which were seen in both mice and humans. Erythrophagocytosis was shown to suppress efferocytosis, suggesting a mechanistic link between these 2 processes. Thus, our studies demonstrate that the mechanisms underlying the proatherogenic effect of Jak2 VF are multifaceted, involving different hematopoietic lineages and their interactions (Figure 8) .
Aberrant hematopoiesis and neutrophil infiltration of lesions were associated with increased early atherosclerosis in Jak2 VF mice, as reported in other models of neutrophil overproduction. 15 Consistent with a major role of neutrophils, increased rolling and firm adhesion of neutrophils was shown by intravital microscopy of carotid arteries in Jak2 VF mice. Platelet activation, neutrophil activation, platelet/neutrophil and platelet/monocyte aggregates which were prominently increased in Jak2 VF mice are known to promote recruitment of inflammatory leukocytes into lesions. 47, 48 Importantly, several of these atherogenic propensities, such as basal platelet P-selectin exposure and platelet-monocyte aggregates, were augmented by interaction of hypercholesterolemia with the Jak2 VF mutation. In addition, hypercholesterolemia interacted with the Jak2 VF to synergistically increase the BM hematopoietic stem cell population, possibly reflecting cross-talk between JAK2VF signaling with signaling pathways that are activated by cholesterol accumulation in hematopoietic stem and progenitor cells. 49 This raises the possibility that hypercholesterolemia could promote the evolution of CH.
Erythophagocytosis has been described as a prominent feature in complex human atherosclerotic lesions and proposed to promote macrophage foam cell formation and lesional necrotic core formation. 17 Erythrocyte and macrophage markers colocalize in or around lesional necrotic cores in advanced human atherosclerotic lesions, suggesting that erythrophagocytosis may contribute to plaque instability. 17 Increased erythrophagocytosis seemed to involve different mechanisms in mouse versus human RBCs-with decreased levels of CD47, a don'teat-me signal in mice, and increased levels of calreticulin, a prophagocytic signal in human RBCs. The mechanisms responsible for increased RBC entry into lesions are uncertain but could involve the observed increase in formation of RBCleukocyte aggregates which could carry RBCs from the arterial lumen into the subendothelial space. One limitation of the study is use of female Ldlr −/− mice only as recipients for atherosclerosis studies. Nevertheless, both male and female mice were used for in vitro assays of erythrophagocytosis, indicating that the altered erythrophagocytosis was not limited to females.
The elevated expression of multiple proinflammatory cytokines and chemokines in Jak2 VF macrophage in response to LPS stimulation suggests that heightened inflammation also contributes to accelerated atherosclerosis in Jak2 VF mice. Increased lesional inflammation could trigger cleavage of cell surface MerTK in macrophages in Jak2 VF mice, Jak2 V617F Promotes Atherosclerosis e45 leading to defective efferocytosis and increased necrotic core formation. 24 Cleavage of macrophage cell surface MerTK is primarily mediated by ADAM17 (ADAM metallopeptidase domain 17), and this process can be upregulated by TLR4 and p38 MAPK signaling 44 which was increased in Jak2 VF macrophages. Therefore, proinflammatory macrophage activation in Jak2 VF mice could exacerbate atherosclerosis by impaired efferocytosis via p38 MAPK and by proinflammatory cytokine and chemokine production. As previously reported, 31 there was no detectable inflammasome activation in WD-fed Ldlr −/− mice transplanted with wild-type BM. However, there was prominent inflammasome activation in splenic CD11b + cells which includes macrophages in Jak2 VF mice. The increased production of IL-1β and possibly IL-18 could also contribute to neutrophilia and neutrophil infiltration detected in Jak2 VF mice. 45, 46, 50 Another shortcoming of our study is that it involved panhematopoietic Jak2 VF and thus abnormalities in hematopoiesis may have contributed more prominently to atherogenesis than in a true CH model. 10 Although prospectively studied CH subjects did not have abnormal blood cell counts at baseline, 51 qualitative changes in blood cell function, as well as development of myelo-proliferation in some patients, 52 seem likely. In humans carrying mutations that cause CH and increased CVD risk, the single abnormality in blood cell phenotypes was an increase in erythrocyte anisocytosis 51 which was also prominent in Jak2 VF mice and is a known CVD risk factor in the general population. 53, 54 We speculate that anisocytosis may be a marker of aberrant erythrocyte properties, possibly reflecting increased erythrocyte production or interactions between inflammatory myeloid cells and erythroblasts in the BM, 55 that predisposes to atherosclerosis, for example by stimulation of erythhrophagocytosis in atherosclerotic lesions.
The recommended treatment for low-risk polycythemia vera patients includes phlebotomy and low dose aspirin. 56, 57 Current recommendations suggest that the hematocrit should be maintained <45% 41 because higher hematocrits are associated with increased cardiovascular death and major thrombosis in polycythemia vera patients. 41 Our findings suggest that Jak2 VF erythrocytes may have a direct role in promoting advanced atherosclerosis and plaque instability, raising the possibility that even lower levels of hematocrit may be desirable. Finally, our findings highlight the importance of increased myelopoiesis, proinflammatory macrophage activation, platelet activation, and PLA (platelet/leukocyte aggregate) formation in atherogenesis, suggesting the need for effective anti-platelet and cytoreductive therapies in MPNs and perhaps in CH. Since many of the underlying atherogenic mechanisms were aggravated by hypercholesterolemia in Jak2 VF mice, control of LDL cholesterol via statins and PCSK9 (proprotein convertase subtilisin/kexin type 9) mAbs (monoclonal antibodies) may be particularly important in patients with JAK2VF-associated MPN or CH. Finally, the recent demonstration in the CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) that IL-1β antibodies reduced coronary heart disease opens a new vista on anti-inflammatory therapies as a treatment for atherosclerosis, 58 and our findings suggest that patients with CH or MPN may particularly benefit from this or other anti-inflammatory therapies.
